Summary
Novigenix SA (Novigenix) is a molecular diagnostics company that develops new generation blood tests for early detection of cancer. The company provides lead product such as colox, a molecular blood test designed to reduce the mortality from colorectal cancer through early detection and colonoscopy. It offers colox which is based on the analysis of peripheral blood mononuclear cells that detects both adenomatous polyps and early stages of colorectal cancer. Novigenix provides technology which is based on a new generation of gene expression profiles of circulating blood cells and tumor-derived protein markers. The company caters through its clinical laboratories located in Switzerland. Novigenix is headquartered in Lausanne, Switzerland.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook